Targeting mesothelin (MSLN) improved neoantigen vaccine efficacy in pancreatic cancer by reducing apCAFs, which disrupted the conversion of naive CD4+ T cells into Tregs and enhanced the infiltration of IFN‐γ+CD4+ and GZMK+CD8+ T cells. The gene discussed is CD4; the disease is pancreatic neoplasm.